The Pharmaceutical Marketing Mix: How the 4Ps and 7Ps Work for Rx, OTC and Consumer Health

FreeScore your brand plan before management does. Send me the scorecard

Every marketing student learns the 4Ps. Many people who move into pharmaceutical marketing then discover that the textbook version does not quite fit. The price may be set by a regulator rather than by the company. The most important customer may never buy the product. Some promotion that is routine in other industries is not allowed at all. And the same company may sell a hospital injectable, a pharmacy painkiller and a dermo-cosmetic cream, each with a completely different mix.

This guide takes the marketing mix as it is taught and shows how each element works in the pharmaceutical industry, with the differences between prescription (Rx), over-the-counter (OTC) and consumer health products made explicit. It is written for brand managers, product managers and commercial teams who need a practical checklist rather than a theory lesson. If you want the bigger picture of how pharma marketing works, who decides and how a strategy is built, start with the cornerstone guide to pharma marketing strategy and come back here when you are ready to put the strategy into practice.

What Is the Marketing Mix in the Pharmaceutical Industry?

The term “marketing mix” was popularised by Neil Borden, and E. Jerome McCarthy grouped its elements into the four Ps in his 1960 textbook Basic Marketing: product, price, place and promotion. In 1981, Bernard Booms and Mary Jo Bitner proposed three more for service businesses: people, process and physical evidence. Together they are known as the 7Ps.

Pharma is not a service business in the narrow sense, but the extra three Ps matter a great deal. A medicine reaches a patient through a chain of people (representatives, pharmacists, doctors, nurses), a set of processes (ordering, sampling, medical information requests, adverse event reporting) and a body of physical evidence (packs, leaflets, approved materials) that builds or erodes trust. Leaving them out of the plan means leaving out much of what the customer actually experiences.

Three things make the pharmaceutical marketing mix different from the mix for an ordinary consumer product:

• Regulation touches every P. What the product can claim, how it is priced, who may sell it and how it may be promoted are all set or limited by health authorities.
• The decision is shared. For many products, the person who chooses (a doctor or pharmacist) is not the person who uses it (the patient) or the one who pays (a payer, an insurer, a hospital or the patient).
• Product type changes everything. A prescription medicine, an OTC medicine and a consumer health product sit under different rules and are chosen by different people, so the same P can mean three different jobs.

How Do the 4Ps and 7Ps Fit With Pharma Strategy?

A common mistake is to start a plan by filling in the 4Ps. That produces a list of activities without a reason. The order that works is: understand the market and the customer, choose where to compete and what the brand stands for, set objectives, and only then decide the product, price, place and promotion that will deliver them. The steps of that process are covered in the guide to building a pharma marketing strategy, and the annual document that holds the decisions together is the pharma brand plan.

Used this way, the mix earns its place as a consistency test. If the strategy says the brand is the pharmacist’s first recommendation for a symptom, then the people, promotion and place decisions must all point at the pharmacy counter. If the pack is hard to find on the shelf or the price is out of line with the category, the mix is telling you the plan has a gap.

How Does Each P Work Differently for Rx, OTC and Consumer Health?

Before looking at each P, it helps to be clear about the three product types, because the rest of this guide keeps returning to them:

• Prescription (Rx) medicines can only be dispensed against a prescription. The prescriber makes the choice, often within a hospital formulary or a payer’s list.
• OTC medicines are registered medicines that can be sold without a prescription, usually in pharmacies. The shopper and the pharmacist decide together, and the pharmacist’s recommendation often tips the choice.
• Consumer health products is a broad term covering vitamins and supplements, dermo-cosmetics, oral care, baby care and similar categories. Depending on the country they may be registered as health products, supplements or cosmetics, each with its own rules on claims.

The sections below take each P in turn. The comparison table that follows them puts the main differences side by side.

Product: the molecule, the format and the lifecycle

In most industries, product decisions are about features and design. In pharma, the core of the product (the active ingredient, its strength and its approved indication) is fixed by the registration file. The marketing team works around that core: the formulation and format, pack sizes, the patient leaflet, the device for an inhaler or an injectable, the range architecture and the lifecycle plan.

For an Rx medicine, product marketing is about evidence and lifecycle. The clinical data defines what the product can be said to do. Over time, the company may add new indications, new formulations (an extended-release version, a fixed-dose combination, a paediatric form) or new devices, each of which needs regulatory approval. When patents expire and generics arrive, the product question becomes how to keep value through brand trust, patient support or a move to OTC status where the regulator allows it.

For an OTC medicine, the product is also what the shopper sees: the brand name, the pack design, the clarity of the indication on the front, the choice of formats (tablets, liquids, sprays, effervescent forms) and the range. Line extensions are a major lever, but they carry a risk: too many variants confuse the shopper and the pharmacist and spread the shelf space thin.

For consumer health, product decisions look most like fast-moving consumer goods: formulation, sensory experience, packaging, range and innovation pace. The difference is that every claim on the pack must match how the product is registered. A dermo-cosmetic cannot make a medicinal claim, and a supplement cannot claim to treat a disease.

Price: regulated, negotiated or set by the market

Price is where the pharmaceutical marketing mix departs furthest from the textbook. In many countries, the price of a registered medicine is reviewed or set by a health authority, often with reference to prices in other countries. Hospital and public sector supply is frequently bought through tenders, where price competes with supply reliability and other criteria. In markets with insurance or public reimbursement, the payer’s decision to cover a medicine can matter more than its list price.

For an Rx medicine, then, price work is mostly about the registration price, the evidence that supports value, tender strategy and the terms agreed with distributors and institutions. The marketing team rarely moves the price itself; it builds the case that justifies it.

For an OTC medicine, the price may still be regulated, but the shopper sees it and compares it on the shelf. The marketing questions become where the brand sits against the category, which pack sizes offer the right entry point, and how promotions and trade terms affect the price the shopper actually pays. Where retail prices are fixed, promotional mechanics such as bundles or gift-with-purchase, where permitted, take the place of price cuts.

For consumer health products that are not registered as medicines, prices are usually set by the company and the retailer, and the full range of consumer pricing tools applies: price tiers, promotions, pack-price architecture and online pricing. That freedom brings the usual risk of eroding the brand through constant discounting.

Place: from manufacturer to patient

Place covers every step that gets the product to the patient: the importer or local agent, the distributor, wholesalers, hospital pharmacies, pharmacy chains, independent pharmacies, e-pharmacy and, for some consumer health products, supermarkets and online marketplaces. In many markets, a licensed distributor is required between the manufacturer and the pharmacy, and the choice of partner shapes coverage, stock availability and the information the brand gets back.

For an Rx medicine, place is about access: hospital formularies, tender wins, availability in the pharmacies that serve the main prescribing centres, and cold-chain or special-handling needs. Stock-outs are especially costly, because a prescriber who switches a patient may not switch back.

For an OTC medicine, place becomes a shelf and counter question. The brand needs listings in the chains that matter, coverage in independent pharmacies, the right position on the shelf or behind the counter, stock before the season, and a presence on e-pharmacy sites that is accurate and well ranked. This is the world of trade marketing, covered in depth in the guide to trade marketing in the pharmaceutical industry. For how chains, independents and distributors fit together in Saudi Arabia specifically, see pharmacy channel management in KSA.

For consumer health, place can extend beyond the pharmacy into grocery, beauty retail and marketplaces, depending on how the product is registered and what each channel is allowed to sell. Each extra channel brings reach and also complexity: different pricing, different shoppers and different expectations of the supplier.

Promotion: who you may speak to, and how

Promotion is the most regulated P. The core rule in most countries is simple: prescription medicines may be promoted only to healthcare professionals, and non-prescription products may be advertised to the public within approved claims and, in many markets, after approval of the advertisement itself. A few countries, notably the United States and New Zealand, allow direct-to-consumer advertising of prescription medicines under rules; most do not.

For an Rx medicine, the promotional mix is directed at healthcare professionals: detailing by medical representatives, scientific meetings and medical education, materials approved by the medical function, digital channels for healthcare professionals, and the work of medical science liaisons, which is scientific exchange rather than promotion. Industry codes and local promotional rules govern what can be said, what can be given and how events are run. Disease awareness for the public may be possible where it does not promote a specific product, but the line is fine and must be checked with the regulatory team.

For an OTC medicine, promotion has two audiences. Consumer advertising (television, digital, social media, outdoor) builds awareness and brand choice, within the approved claims. Pharmacy activation builds recommendation and conversion: pharmacist and counter staff education, in-store visibility, shelf materials and promotions agreed with the accounts. In many OTC categories, the pharmacist’s recommendation is the lever that decides the sale at the counter.

For consumer health, promotion looks closest to consumer goods: brand advertising, influencer and creator content, sampling, retail media and e-commerce content. The regulatory limits still apply to claims, and in some markets to the approval of advertisements, so speed must be planned around review time rather than at its expense.

People: representatives, pharmacists and the team behind them

People is the P that pharma companies spend most on and plan least. For Rx brands, it means the field force (medical representatives, key account managers for hospitals and institutions), the medical team (medical science liaisons, medical information) and the patient support staff where programmes exist. Their training, call quality and credibility often decide whether a prescriber trusts the brand.

For OTC and consumer health brands, the most important people often do not work for the company at all. Pharmacists and pharmacy assistants answer the shopper’s question at the counter. Beauty advisors in pharmacies recommend dermo-cosmetics. The company’s own people (pharmacy representatives, merchandisers, key account managers for chains) matter mainly through how well they equip those front-line recommenders.

Process: how the customer experiences the company

Process covers the steps that customers go through when they deal with the brand. For a prescriber, that includes how easy it is to request information or samples where permitted, how quickly a medical question is answered, and how simply an adverse event can be reported. For a pharmacy, it includes ordering, delivery reliability, returns, payment terms and how promotions are claimed. For a patient, it can include a support programme, a helpline or a reminder service.

Process rarely features in brand plans, yet a slow order cycle or a confusing claims process can cancel the effect of a good promotion. Behind every customer-facing process in pharma sits an internal one: the medical, legal and regulatory review of materials. Planning around that review time is part of the process P.

Physical evidence: what the customer can see and touch

In service marketing, physical evidence is the tangible proof of an intangible service. In pharma, it is everything that signals quality and trust: the pack, its readability and tamper evidence, the patient leaflet, approved materials for professionals, the brand’s shelf presence, its e-pharmacy product pages and its website. For an Rx brand, a well-designed pack and leaflet support correct use. For an OTC or consumer health brand, the pack on the shelf is often the last piece of marketing the shopper sees before choosing.

What Is the Difference Between the Rx and OTC Marketing Mix?

The table below summarises how each of the seven Ps typically differs. The details vary by country and by product, so treat it as a starting point to check against local rules rather than a fixed rulebook.

The pattern in the table is that the further a product moves from prescription towards consumer health, the more the mix shifts from professional persuasion to shopper choice, and the more the shelf and the screen matter. Companies that run all three types often make the mistake of applying one mix to all of them, for example detailing a dermo-cosmetic as if it were an Rx product, or running an OTC brand without any pharmacist education.

FreeScore your brand plan before management does. Send me the scorecard

Are There Alternatives to the 4Ps for Pharma?

Lauterborn argued that the 4Ps describe what the seller controls and proposed four customer-centred equivalents: the consumer’s wants and needs instead of product, cost to satisfy instead of price, convenience to buy instead of place, and communication instead of promotion. In pharma, the 4Cs are a helpful way to test a plan from the patient’s or the prescriber’s point of view. Cost, for example, includes the time and effort of getting a prescription filled, not only the price on the pack. Convenience includes whether the product is in stock in the pharmacy the patient actually uses.

Whichever framework you use, the point is the same: list every lever that affects the customer’s choice, make sure each one supports the strategy, and check each one against the rules.

What Changes in Saudi Arabia and the GCC?

In Saudi Arabia, several elements of the mix are set or limited by the SFDA, and the other GCC regulators work on broadly similar principles, with differences in detail. Kept at a general level, the main points for planning are:

• Product: how a product is registered (medicine, health product or supplement, cosmetic) decides what it can claim and how it can be marketed. Settle the category before planning anything else.
• Price: the prices of registered medicines are regulated, so the marketing team works within an approved price rather than setting one. Public sector supply runs largely through centralised procurement and tenders.
• Place: medicines reach pharmacies through licensed distributors and a mix of large pharmacy chains, independent pharmacies and growing e-pharmacy channels.
• Promotion: prescription medicines cannot be promoted to the public. Promotion to healthcare professionals must follow the Saudi promotional code. Consumer-facing advertising for non-prescription medicines and health products needs SFDA’s prior approval.

Rules change, and the detail matters, so treat this as a map of where to look rather than as legal advice. For a practical checklist of what needs approval by channel and how the approval flow works inside a company, see the SFDA marketing compliance checklist.

What Does a Pharma Marketing Mix Example Look Like?

The brand, its products and its situation below are fictional and used only to illustrate the method. No figures are given because real targets depend on the category, the market and the data you have.

The situation. “Brand R” (a fictional brand) is a registered OTC cold and flu range sold through pharmacies. Shoppers know the name but do not ask for it, and pharmacists recommend competing brands more often. The strategy in the brand plan is to make Brand R the pharmacist’s first recommendation for adults with cold symptoms, while building enough consumer awareness that shoppers accept that recommendation easily.

Two things make this a mix rather than a list. First, every line traces back to one strategic choice. Second, the levers reinforce each other: the simpler range makes the education easier, the education is worth more when stock is reliable, and the consumer advertising makes the pharmacist’s recommendation easier to accept. For how a launch sequences these levers over time, from opportunity assessment to the first 90 days, see the guide to an OTC product launch in Saudi Arabia, which covers the launch marketing mix phase in detail.

How Do You Build a Pharmaceutical Marketing Mix, Step by Step?

1. Confirm the product type and its rules. Is it Rx, OTC or consumer health, and how exactly is it registered? This decides which levers are open.
2. Name the decision-maker. Who chooses the product: the prescriber, the pharmacist, the shopper, a hospital committee, a payer? Most products have more than one, so rank them.
3. Write the strategic choice in one sentence. Who is the target, what should they believe or do, and why should they choose this brand? If you cannot write it, go back to the strategy.
4. Decide each P against that choice. For each of the seven, write what you will do, what you will stop doing, and why.
5. Check the Ps against each other. Look for contradictions: premium positioning with constant discounting, heavy advertising with poor distribution, a large range with no shelf space.
6. Check every line against the rules. Claims, promotion, pricing and incentives all need to be reviewed with the regulatory and medical teams before money is committed.
7. Set measures for each P. Distribution and stock for place, recommendation and awareness for promotion, execution quality for people and process. Use measures you can actually source, and leave placeholders until a baseline exists.

The output of these steps is not a separate document. It feeds the brand plan, where the decisions are given owners, a calendar and a budget. The structure for that document is in the guide to the pharma brand plan.

What Are the Most Common Marketing Mix Mistakes in Pharma?

• Starting with the Ps. A mix written before the strategy becomes a list of activities. Decide the target and the position first.
• One mix for every product type. Rx, OTC and consumer health brands are chosen by different people under different rules. Applying the same playbook to all three wastes money on at least two of them.
• Promotion carrying the whole plan. Advertising and detailing are the visible levers, so they get the attention. A brand with weak distribution or poor stock will not be rescued by more promotion.
• Ignoring price because it is regulated. Even when the list price is fixed, pack sizes, trade terms, tender strategy and permitted promotions all shape what customers pay and how they judge value.
• Forgetting people, process and physical evidence.The pharmacist’s confidence, the reliability of supply and the readability of the pack often decide the sale more than the campaign does.
• Too many line extensions. Each new variant needs shelf space, stock, education and approval. A range that grows without a clear role for each item confuses shoppers and pharmacists alike.
• Planning without review time. In a regulated industry, every claim and material needs medical, legal and regulatory review. A mix that ignores that lead time arrives late.
• Copying another market’s mix. What is allowed, how pharmacies operate and how prices are set all differ by country. A mix that worked elsewhere must be rebuilt for the local rules and channels, not translated.

Key Takeaways

• The pharmaceutical marketing mix is the 4Ps plus people, process and physical evidence, applied inside regulation
• Each P works differently for Rx, OTC and consumer health because the decision-maker and the rules differ
• Rx promotion is limited to healthcare professionals in most countries, including Saudi Arabia and the GCC
• For OTC brands, the pharmacist and the shelf are central levers, alongside approved consumer advertising
• Price still matters when it is regulated: pack sizes, trade terms and tenders shape value
• Build the mix after the strategy and check every line against the rules before committing budget

Frequently Asked Questions

What to Do Next

Take one brand you manage and fill in the comparison table above for it alone: one column, seven rows, one line per P. Then read the rows against your one-sentence strategy and mark any P that does not support it. Those marks are the first changes to make in your next plan.

For the wider context of how pharma marketing works, who decides and how a strategy is built, return to the cornerstone guide to pharma marketing strategy.